<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">SMM</journal-id>
<journal-id journal-id-type="hwp">spsmm</journal-id>
<journal-id journal-id-type="nlm-ta">Stat Methods Med Res</journal-id>
<journal-title>Statistical Methods in Medical Research</journal-title>
<issn pub-type="ppub">0962-2802</issn>
<issn pub-type="epub">1477-0334</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0962280213482391</article-id>
<article-id pub-id-type="publisher-id">10.1177_0962280213482391</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Editorial</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Meta-analysis in clinical research</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Julious</surname><given-names>Steven A</given-names></name>
<xref ref-type="corresp" rid="corresp1-0962280213482391"/>
</contrib>
<aff id="aff1-0962280213482391">University of Sheffield, UK</aff>
</contrib-group>
<contrib-group content-type="issue">
<contrib contrib-type="guest-editor">
<name><surname>Julious</surname><given-names>Steven A</given-names></name>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-0962280213482391">Steven A Julious, Medical Statistics Group, ScHARR, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK. Email: <email>S.A.Julious@Sheffield.ac.uk</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>2</issue>
<issue-title>Special Issue: Meta analysis in Clinical Research</issue-title>
<fpage>115</fpage>
<lpage>116</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013 Reprints and permissions sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>Meta-analysis is important in the evaluation of therapies<sup><xref ref-type="bibr" rid="bibr1-0962280213482391">1</xref>,<xref ref-type="bibr" rid="bibr2-0962280213482391">2</xref></sup> for integrating the results of individual studies in order to advance or inform clinical research. In this special issue, different aspects of meta-analysis are reviewed using case studies to illustrate the methodologies being described.</p>
<p>There can be issues when evaluating evidence when the events being observed are rare.<sup><xref ref-type="bibr" rid="bibr3-0962280213482391">3</xref></sup> Lane compares available methods for binary data considering different summary measures such as risk-difference, relative-risk and odds-ratio scale as well as fixed and random-effect methods in the assessment. The paper also highlights the benefit of how graphical approaches can add value.<sup><xref ref-type="bibr" rid="bibr4-0962280213482391">4</xref></sup></p>
<p>A case study is presented by Julious to highlight issues in evaluating evidence for safety and efficacy, which updates previous analyses with additionally reported trials.<sup><xref ref-type="bibr" rid="bibr5-0962280213482391">5</xref></sup> These data also consider the problem of the event of interest being rare. Graphical approaches are highlighted to investigate the assumptions in a meta-analysis.<sup><xref ref-type="bibr" rid="bibr6-0962280213482391">6</xref></sup></p>
<p>Often, however, a direct comparison of two therapies is not possible and indirect comparisons need to be made through a network meta-analysis.<sup><xref ref-type="bibr" rid="bibr7-0962280213482391">7</xref></sup> A sparsely connected network of 10 treatments for the treatment of diabetes is used by Senn et al. to make points about approaches to analysis.<sup><xref ref-type="bibr" rid="bibr8-0962280213482391">8</xref></sup> Graphical approaches, both of the network and of the results, are again described to summarise the data.</p>
<p>Indirect comparisons are also used in the assessment, and design, of non-inferiority studies.<sup><xref ref-type="bibr" rid="bibr9-0962280213482391">9</xref>,<xref ref-type="bibr" rid="bibr10-0962280213482391">10</xref></sup> In non-inferiority clinical trials, a test treatment is compared to an active-control rather than to placebo – when randomising to placebo is unethical or not feasible. A critical question is whether the test treatment would have been superior to placebo, had placebo been used in the non-inferiority trial.<sup><xref ref-type="bibr" rid="bibr11-0962280213482391">11</xref>,<xref ref-type="bibr" rid="bibr12-0962280213482391">12</xref></sup> This question, as highlighted by Schmidli et al.,<sup><xref ref-type="bibr" rid="bibr13-0962280213482391">13</xref></sup> can only be addressed indirectly, based on information from relevant historical trials with data on active-control and placebo.</p>
<p>As highlighted multivariate meta-analysis is becoming increasingly popular. The advantages and limitations of multivariate meta-analysis have been discussed.<sup><xref ref-type="bibr" rid="bibr14-0962280213482391">14</xref></sup> The main limitation being computational complexity and hence, in a timely paper, Mavridis and Salanti<sup><xref ref-type="bibr" rid="bibr15-0962280213482391">15</xref></sup> review the statistical methods and the related software for multivariate meta-analysis.</p>
<p>Pooling evidence from individual trials is important in the evaluation of research. For the individual trials adaptive designs have been recommended.<sup><xref ref-type="bibr" rid="bibr16-0962280213482391">16</xref>,<xref ref-type="bibr" rid="bibr17-0962280213482391">17</xref></sup> However, there can be issues in pooling evidence when trials have stopped early.<sup><xref ref-type="bibr" rid="bibr18-0962280213482391">18</xref>,<xref ref-type="bibr" rid="bibr19-0962280213482391">19</xref></sup> Bassler et al.<sup><xref ref-type="bibr" rid="bibr20-0962280213482391">20</xref></sup> review controversies associated with randomised controlled trials stopped early for apparent benefit and discussed how pooled effects from meta-analyses including trials stopped early could potentially overestimate an effect.</p>
<p>In summary, this special issue covers many practical issues with meta-analysis. There is a strong emphasis on graphical approaches to assist in interpretation. There have been many advances in recent years in meta-analysis – such as indirect approaches via networks – and these are discussed in detail.</p>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="bibr1-0962280213482391"><label>1</label><citation citation-type="journal"><comment>Whitehead A. <italic>Meta-analysis of controlled clinical trials</italic>, Chichester: Wiley</comment>.</citation></ref>
<ref id="bibr2-0962280213482391"><label>2</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Senn</surname><given-names>SJ</given-names></name></person-group>. <source>Statistical issues in drug development</source>, <edition>2nd ed</edition>. <publisher-loc>Hoboken</publisher-loc>: <publisher-name>Wiley</publisher-name>, <year>2007</year>.</citation></ref>
<ref id="bibr3-0962280213482391"><label>3</label><citation citation-type="other"><comment>Lane PW. Meta-analysis of incidence of rare events. <italic>Stat Meth Med Res</italic> 2013; <bold>22</bold>(2): 117--132</comment>.</citation></ref>
<ref id="bibr4-0962280213482391"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amit</surname><given-names>O</given-names></name><name><surname>Heiberger</surname><given-names>R</given-names></name><name><surname>Lane</surname><given-names>PW</given-names></name></person-group>. <article-title>Graphical approaches to the analysis of safety data from clinical trials</article-title>. <source>Pharmaceut Stat</source> <year>2008</year>; <volume>7</volume>: <fpage>20</fpage>–<lpage>35</lpage>.</citation></ref>
<ref id="bibr5-0962280213482391"><label>5</label><citation citation-type="other"><comment>Julious SA. Efficacy and suicidal risk for antidepressants in paediatric and adolescent patients. <italic>Stat Meth Med Res</italic> 2013; <bold>22</bold>(2): 190--218</comment>.</citation></ref>
<ref id="bibr6-0962280213482391"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Julious</surname><given-names>SA</given-names></name><name><surname>Whitehead</surname><given-names>A</given-names></name></person-group>. <article-title>Investigating the assumption of homogeneity of treatment effects in clinical studies with application to meta-analysis</article-title>. <source>Pharmaceut Stat</source> <year>2012</year>; <volume>11</volume>(<issue>1</issue>): <fpage>49</fpage>–<lpage>56</lpage>.</citation></ref>
<ref id="bibr7-0962280213482391"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salanti</surname><given-names>G</given-names></name><name><surname>Higgins</surname><given-names>JP</given-names></name><name><surname>Ades</surname><given-names>AE</given-names></name><etal/></person-group>. <article-title>Evaluation of networks of randomized trials</article-title>. <source>Stat Meth Med Res</source> <year>2008</year>; <volume>17</volume>(<issue>3</issue>): <fpage>279</fpage>–<lpage>301</lpage>.</citation></ref>
<ref id="bibr8-0962280213482391"><label>8</label><citation citation-type="other"><comment>Senn S, Gavini F, Magrez D, et al. Issues in performing a network meta-analysis. <italic>Stat Meth Med Res</italic> 2013; <bold>22</bold>(2): 169--189</comment>.</citation></ref>
<ref id="bibr9-0962280213482391"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Julious</surname><given-names>SA</given-names></name><name><surname>Wang</surname><given-names>SJ</given-names></name></person-group>. <article-title>Issues with indirect comparisons in clinical trials particularly with respect to non-inferiority trials</article-title>. <source>Drug Inform J</source> <year>2008</year>; <volume>42</volume>(<issue>6</issue>): <fpage>625</fpage>–<lpage>633</lpage>.</citation></ref>
<ref id="bibr10-0962280213482391"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Julious</surname><given-names>SA</given-names></name></person-group>. <article-title>The ABC of non-inferiority margin setting from indirect comparisons</article-title>. <source>Pharmaceut Stat</source> <year>2011</year>; <volume>10</volume>(<issue>5</issue>): <fpage>448</fpage>–<lpage>453</lpage>.</citation></ref>
<ref id="bibr11-0962280213482391"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Witte</surname><given-names>S</given-names></name><name><surname>Schmidli</surname><given-names>H</given-names></name><name><surname>O'Hagan</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Designing a non-inferiority study in kidney transplantation: a case study</article-title>. <source>Pharmaceut Stat</source> <year>2011</year>; <volume>10</volume>: <fpage>427</fpage>–<lpage>432</lpage>.</citation></ref>
<ref id="bibr12-0962280213482391"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Julious</surname><given-names>SA</given-names></name><name><surname>Owen</surname><given-names>RJ</given-names></name></person-group>. <article-title>A comparison of methods for sample size estimation for non-inferiority studies with binary outcomes</article-title>. <source>Stat Meth Med Res</source> <year>2011</year>; <volume>20</volume>(<issue>6</issue>): <fpage>595</fpage>–<lpage>612</lpage>.</citation></ref>
<ref id="bibr13-0962280213482391"><label>13</label><citation citation-type="other"><comment>Schmidli H, Wandel S and Neuenschwander B. The network meta-analytic-predictive approach to non-inferiority trials. <italic>Stat Meth Med Res</italic> 2013; <bold>22</bold>(2): 219--240</comment>.</citation></ref>
<ref id="bibr14-0962280213482391"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ishak</surname><given-names>KJ</given-names></name><name><surname>Platt</surname><given-names>RW</given-names></name><name><surname>Joseph</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Impact of approximating or ignoring within-study covariances in multivariate meta-analyses</article-title>. <source>Stat Med</source> <year>2008</year>; <volume>27</volume>: <fpage>670</fpage>–<lpage>686</lpage>.</citation></ref>
<ref id="bibr15-0962280213482391"><label>15</label><citation citation-type="other"><comment>Mavridis D and Salanti G. A practical introduction to multivariate meta-analysis. <italic>Stat Meth Med Res</italic> 2013; <bold>22</bold>(2): 133--158</comment>.</citation></ref>
<ref id="bibr16-0962280213482391"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stallard</surname><given-names>N</given-names></name><name><surname>Todd</surname><given-names>S</given-names></name></person-group>. <article-title>Seamless phase II/III designs</article-title>. <source>Stat Meth Med Res</source> <year>2011</year>; <volume>20</volume>(<issue>6</issue>): <fpage>623</fpage>–<lpage>634</lpage>.</citation></ref>
<ref id="bibr17-0962280213482391"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whitehead</surname><given-names>J</given-names></name></person-group>. <article-title>Group sequential trials revisited: simple implementation using SAS</article-title>. <source>Stat Meth Med Res</source> <year>2011</year>; <volume>20</volume>(<issue>6</issue>): <fpage>635</fpage>–<lpage>656</lpage>.</citation></ref>
<ref id="bibr18-0962280213482391"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bassler</surname><given-names>D</given-names></name><name><surname>Briel</surname><given-names>M</given-names></name><name><surname>Montori</surname><given-names>VM</given-names></name><etal/></person-group>. <article-title>Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis</article-title>. <source>JAMA</source> <year>2010</year>; <volume>303</volume>: <fpage>1180</fpage>–<lpage>1187</lpage>.</citation></ref>
<ref id="bibr19-0962280213482391"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mueller</surname><given-names>PS</given-names></name><name><surname>Montori</surname><given-names>VM</given-names></name><name><surname>Bassler</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Ethical issues in stopping randomized trials early because of apparent benefit</article-title>. <source>Ann Intern Med</source> <year>2007</year>; <volume>146</volume>: <fpage>878</fpage>–<lpage>881</lpage>.</citation></ref>
<ref id="bibr20-0962280213482391"><label>20</label><citation citation-type="other"><comment>Bassler D, Montori VM, Briel M, et al. Reflections on meta-analyses involving trials stopped early for benefit: is there a problem and if so, what is it? <italic>Stat Meth Med Res</italic> 2013; <bold>22</bold>(2): 159--168</comment>.</citation></ref>
</ref-list>
</back>
</article>